Compare Kraft Heinz Co (KHC) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kraft Heinz Co vs Recursion Pharmaceuticals Inc — how do they compare? Kraft Heinz Co trades at $22.27 (market cap $26.66B), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: Kraft Heinz Co is far larger — about 12.5× Recursion Pharmaceuticals Inc's market cap, and Kraft Heinz Co pays a 7.12% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kraft Heinz Co for 129 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| KHC | RXRX | |
|---|---|---|
Market Cap | $26.66B | $2.14B |
Volume | 31,300,109 | 30,789,535 |
Sector | Consumer Staples | Health |
52-Week High | $27.62 | $6.79 |
52-Week Low | $21.21 | $2.84 |
Typical Hold Time | 129 Days | 23 Days |
Enterprise Value | $42.98B | $1.66B |
Dividend Yield | 7.12% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kraft Heinz (KHC) trades at $22.48, up 2.27% today, but remains in a bearish technical trend. The company reported a net loss of $5.85 billion in 2025 due to a significant impairment charge, though recent quarters have beaten EPS estimates. Operating cash flow remains strong at $4.46 billion, supporting a $0.40 dividend. News highlights focus on brand revitalization efforts, such as new Philadelphia cream cheese flavors, as part of a broader turnaround strategy.
The outlook is mixed: valuation metrics like P/B of 0.74 suggest potential undervaluation, but persistent net losses and high debt pose risks. Analyst sentiment is cautious with a consensus price target of $24.50. The stock's near-term direction hinges on successful execution of cost management and volume recovery initiatives amid competitive pressures.
Recursion Pharmaceuticals (RXRX) trades at $3.95, down 7.49% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss after two consecutive beats, while maintaining negative profitability metrics with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche aim to expand the AI-driven drug discovery pipeline through 2028.
RXRX presents high-risk growth potential with strong analyst support (40% buy rating) but faces substantial financial challenges including persistent losses and negative cash flow from operations. The stock's investment case hinges on successful pipeline development and partnership monetization, though current valuation appears stretched at 37.14x sales given the lack of profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
